Hantschel, Oliver

The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib

Hantschel, O., Rix, U., Schmidt, U., Bürckstümmer, T., Kneidinger, M., Schütze, G., Colinge, J., Bennett, K. L., Ellmeier, W., Valent, P., et al. (2007) · Proceedings of the National Academy of Sciences

Chronic Myeloid Leukemia TreatmentsMast cells and histamine

Cited by 284

Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib

Hantschel, O., Rix, U., & Superti-Furga, G. (2008) · Leukemia & Lymphoma

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 256

BCR::ABL1 kinase N-lobe mutants confer moderate to high degrees of resistance to asciminib

Leyte-Vidal, A., Garrido Ruiz, D., DeFilippis, R., Leske, I. B., Rea, D., Phan, S., Miller, K. B., Hu, F., Mase, A., Shan, Y., et al. (2024) · Blood

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 40

The e13a3 (b2a3) and e14a3 (b3a3) BCR::ABL1 isoforms are resistant to asciminib

Leske, I. B., & Hantschel, O. (2024) · Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 35